Atreca
South San Francisco
About Atreca
Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $347.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2020)
- Ticker: nasdaq:BCEL
- Website: atreca.com
- Phone: 6505952618
Industries & Categories
Biotechnology, Health Care, Product Research, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/atreca-68027 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.